Introduction
The phenomenal expansion of our knowledge in molecular biology of cancer in the last decade has led to an unprecedented number of exciting new targets for cancer treatment. A typical oncology drug candidate has many developmental opportunities as determined by line of therapy and tumor type, making it a hard decision as how to proceed amid uncertainties inherent in preclinical and early clinical data (dosing schedules, combination therapies and existence of a possible response signature further complicates the issue.)